JP Morgan Says Jazz Pharmaceuticals Positioned For 'Organic Growth And Acquisition'
Shares of Jazz Pharmaceuticals (NASDAQ: JAZZ) are up almost 20 percent over the past five trading sessions.
JP Morgan started coverage of the company with an Overweight rating and $190 price target.
"In the context of an ongoing wave of consolidation in the specialty pharmaceuticals sector, we see Jazz as well positioned from both an organic growth and acquisition standpoint," writes analyst Jessica Fye.
Related Link: Leerink Says Tekmir Is 'Uniquely Positioned'
JP Morgan further comments that the company is diversifying away from from its core asset with acquisitions. The company has a borrowing allowance of $3 billion.
On Tuesday, Dow Jones reported Allergan (NYSE: AGN) is interested in purchasing Salix Pharmaceuticals (NASDAQ: SLXP), a competitor in the acquisition space. This news moved Jazz almost four percent higher to $158.14.
Latest Ratings for JAZZ
|Feb 2017||Evercore ISI Group||Initiates Coverage On||Buy|
|Dec 2016||Cantor Fitzgerald||Initiates Coverage On||Overweight|
|Aug 2016||Janney Capital||Initiates Coverage on||Neutral|
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.